YPrime Releases Interactive Response Technology Version 2.0
The most advanced IRT user interface available.
On Monday November 17th, 2014, eClinical software pioneer, YPrime, LLC released their latest addition to the YPrime clinical research software suite. Version 2.0 of their Interactive Response Technology (IRT) product is now available to pharmaceutical companies, academic institutions, and contract research organizations. Prime IRT 2.0 helps sponsors reduce their costs and timeline by utilizing configurable architecture, visual build process, and intuitive user-minded components.
Attendees at a recent industry conference in Philadelphia, PA agreed that the new platform offers, "The most advanced user interface available." YPrime's Director of Product Strategy and Innovation, Bryan Clayton, says, "We spent a lot of time making sure we can deliver a product that addresses real needs in clinical research." Clayton adds, "It is a highly configurable system that still maintains the capability to be customized."
The software builds on the pre-validated module philosophy of its version 1.2 predecessor, but also introduces several new enhancements including: re-architected reporting platform, one-click access to patient data, and robust clinical supply management. "We've heard from our clients that they need an eClinical partner that makes their job easier; not harder. That core philosophy is apparent throughout version 2.0," reports YPrime CEO Shawn Blackburn.
YPrime eClinical software currently supports over 10,000 system users, 2,500 clinical sites, and 13,000 patients in 35 countries. IRT version 2.0 is a cloud-hosted solution able to be translated to virtually all languages, and can be delivered through web browser, phone, or mobile device. The product also links seamlessly to other components of YPrime's eclinical platform including: Electronic Patient Reported Outcomes (ePRO), Electronic Clinical Supply Forecasting (eCSF), and Electronic Monitoring Visit Report (eMVR).
For more detailed information on Prime IRT 2.0, visit www.yprime.com/products/#irt or call 1-844-299-9208.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
